T‐cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments
- 19 January 2024
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (3) , 494-496
Abstract
Survival remains poor for T-cell prolymphocytic leukemia, though treatment in recent years, associated with access to novel therapies, and management at academic medical centers is associated with improved outcomes. There remains a critical need to improve the available treatment options for this population, and access to specialized academic medical centers, comprehensive supportive care, clinical trials, and early palliative care remains essential for T-PLL patients.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (1R38HL143605‐01)
- National Cancer Institute (R50CA275929)
This publication has 5 references indexed in Scilit:
- Advances and Perspectives in the Treatment of T-PLLCurrent Hematologic Malignancy Reports, 2020
- Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaBlood, 2019
- Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)Annals of Oncology, 2017
- Survival trends in T cell prolymphocytic leukemia: A SEER database analysisLeukemia & Lymphoma, 2015
- How I treat prolymphocytic leukemiaBlood, 2012